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Summary The effects of an aromatic retinoid, etretinate and a vinca alkaloid, vindesine were investigated by
culture of malignant melanoma cells in vitro with these two agents; either separately or in combination.
Etretinate inhibited growth of a murine melanoma but only minimal effects were recorded with two human
melanomas. Vindesine however, was inhibitory for all of the cell lines and this effect was enhanced in the
presence of the retinoid. Entry of 3H labelled vindesine or etretinate into drug free cells was followed in the
absence or presence of unlabelled drug. It was found that etretinate enhanced cellular uptake of vindesine in
two of the cell lines and this may be responsible for the enhanced toxicity of vindesine in the presence of
etretinate. The human melanoma which did not exhibit retinoid stimulated vindesine uptake, appeared to be
intrinsically sensitive to the vinca alkaloid. No effect on cellular retinoid uptake by vindesine was recorded in
any of the melanomas. The results indicate that the intracellular concentrations combined with the intrinsic
sensitivities ofeach cell line to etretinate and vindesine determines the toxic response.
The ability of retinoids to enhance the
differentiation of malignant cells is one of their
important properties of relevance to cancer
prevention and therapy (Sporn & Roberts, 1983).
Alone or as adjuvants to cancer chemotherapy,
retinoids exhibit antitumour activities by inhibiting
the growth of malignant cells in vivo (Cohen &
Carbone, 1972). They are, in effect, suppressing the
phenotypic expression of malignancy by promoting
cell differentiation (Sherman et al., 1981). Various
studies suggest that retinoids exert a hormone-like
control of either cell proliferation or cell
differentiation, or both by acting through specific
genetic mechanisms (Astrup & Paulsen, 1982).
Retinoids are also known to affect and modify cell
membrane glycosylation and this could result in an
alteration in the uptake of nutrients and cytotoxic
agents (Lotan, 1980).
An early report using allogeneic growth of the
murine S91 melanoma showed that growth was
inhibited by retinyl palmitate (Gainer et al., 1976)
whereas other workers have not been able to show
an inhibiting effect (Felix et al., 1975). Meyskens &
Salmon (1979) showed that various retinoids
including etretinate had inhibitory effects on the
colony forming ability of human melanoma in soft
agar culture. However, Hoal et al. (1982) reported
variable effects that were dependent upon the
responsiveness of the cells and not the efficacy of
the retinoid. The present work was undertaken to
attempt to clarify this paradoxical situation and
furthermore, using human material, to obtain
results ofclinical relevance.
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Vindesine (23-amino-4-deacetoxy-4-hydroxy-
vincaleukoblastine sulphate) has been reported to
significantly prolong the life of mice bearing the
experimental B16 melanoma (Dyke & Nelson,
1977) and has been shown to be clinically active
against human malignant melanoma (Retsas et al.,
1980; Carmichael et al., 1982). The precise
mechanism by which vinca alkaloids act is not fully
understood although kinetic studies have shown
that the vinca alkaloids interfere with mitosis and
kill cells which are synthesising DNA (Tucker et
al., 1977). Vindesine has also been shown to inhibit
RNA and protein synthesis at concentrations that
inhibit cell survival (Hill & Whelan, 1980).
For this study, vindesine was used in
combination with the aromatic retinoid, etretinate
(Roche 10-9359). Studies were undertake to
elucidate the mechanism of action of these
substances in combination and as a result suggest
possible ways of improving their therapeutic
efficacy in the treatment of malignant melanoma.
Materials and methods
The cell lines used, cell culture techniques employed
and drug uptake protocol have already been
described in detail (Gaukroger et al., 1983, 1984).
Vindesine and tritium labelled vindesine (desacetyl
[G-3H] vinblastine amide sulphate) were obtained
from Eli Lilly & Co. Ltd., Basingstoke, Hampshire,
UK. Etretinate (Ro 10-9359) and G-3H labelled
etretinate were obtained from Roche Products Ltd,
Welwyn Garden City, Hertfordshire, UK.
Concentrated stock solutions of the drugs were
stored protected from light in methanol at -70°C
and diluted in distilled water immediately prior to
use.
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Cells were grown in RPMI1640 containing 10%
calf serum in 25cm2 culture flasks and duplicates
were set up for each experimental point examined.
Aliquots of cells were randomly inoculated into
5 ml of medium at a density of 5 x104 cells per
flask and incubated for 7 days in an atmosphere of
5% CO2 in air in the dark. Sterile additions were
made as required in complete medium. Cell
numbers were determined following suspension in a
calcium/magnesium free EDTA solution by
counting on a Coulter Counter (model Dn with
coincidence correction). Results are expressed as a
percentage of cell survival relative to the control.
(Mean of two experiments in duplicate +sd.) All
tissue culture materials were purchased from Gibco
Ltd., Scotland.
Results
Single agent profiles
The effect of vindesine as a single agent on the
survival of melanoma cells in culture is shown in
Figure 1. All three cell lines exhibit essentially
similar dose-response profiles, with the ID50 values
and the corresponding Do values listed in Table I.
No survival was seen at concentrations > 10-7 M
when cells were cultured in continuous contact with
this agent. Etretinate dose-response profiles are
shown in Figure 2 and it can be seen that no ID50
values were determined for the two human
melanoma lines. The PG19 murine melanoma
however, exhibited greater sensitivity and an ID50
of 1 x 10-6 M was recorded (Table I). Do values of
lxlO-9 (B8), ixlO-9 (B1O) and IxIO-12M
(PG19) were recorded (Table I).
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Table I Do and ID50 values for vindesine and
etretinate for the PG19 (murine), B8 and BiO
(human) melanomas
Cell lines PGJ9 B8 B10
Do vindesine
Single 1x 10-12 1 x 10-13 1 x 10-11
Equimolar 1 x 10-12 1 x 10-12 1 x 10-12
Etretinate 1 x 10-13 1 x 10-13 5 x 10-13
ID50 vindesine
Single 1x 10-9 5 x 10-10 8 x 10-10
Equimolar 3x10-10 6xl-11 6x10-10
Etretinate 2 x 10-9 3 x 10-10 2 x 10-9
Do etretinate
Single Ix10-12 lx10-9 x10-9
Vindesine lIx101 5x 1010 l x 10-9
ID50 etretinate
Single I x 10-6
Vindesine 2 x 10-6
Experiments were performed in the presence of
each agent separately (single) or in the presence of
both agents (equimolar). Experiments were also
carried out in which the concentration of one agent
was constant (10' M for etretinate or 10- l M for
vindesine) and the concentration of the other
varied.
Drug combination profiles - equimolar
When cells were cultured in an equimolar mixture
of vindesine and etretinate the dose-response
profiles shown in Figure 3 were obtained, and are
similar to the single agent profiles of vindesine. The
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Figure 1 Response profiles for survival of (a) PGl9 (murine), (b) B8 and (c) B1O (human) melanoma cells in
the presence ofmolar concentrations ofvindesine.CYTOTOXICTY OF ETRETINATE AND VINDESINE 371
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Figure 2 Response profiles for survival of (a) PGl9 (murine), (b) B8 and (c) BlO (human) melanoma cells in
the presence ofmolar concentrations ofetretinate.
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Figure 3 Response profiles for survival of (a) PGl9 (murine), (b) B8 and (c) B1O (human) melanoma cells in
the presence ofequimolar concentrations of vindesine and etretinate.
ID50 values recorded for continuous contact with
the two agents are shown in Table I, and indicate
slightly increased sensitivity to the drug
combination when compared to vindesine alone.
Vindesine titrations
Cells were grown in the presence of 10-7 M
etretinate and the effect of vindesine on cell survival
is shown in Figure 4. The ID50 concentrations for
vindesine are given in Table I. These values are
similar to the concentrations obtained for vindesine
alone, although the Do values were reduced slightly.
Etretinate titrations
Cells were grown in the presence of 10-I M
vindesine and the effect of etretinate on cell survival
was studied at various concentrations (Figure 5).
For PGI9 cells an ID50 of 2x10-6M was
recorded, but no ID50 values were achieved for the
human melanoma cell lines as previously observed
for etretinate alone. Vindesine (10-11 M) did affect
the survival of the B8 cell line and this was
superimposed on the etretinate toxicity. However,
B8 cell survival was not reduced to the same extent
over the total dose-response curve and at higher
etretinate concentrations growth was inhibited to a
greater extent than expected when compared to
survival in the presence of etretinate alone. The B1O
cell line did not show any reduction in survival to
I0-II M vindesine as expected (Figure 1).
Uptake oflabelled drugs
3H-vindesine The uptake profiles of the three cell
lines are shown in Figure 6, and are essentially the
same with uptake approaching a plateau between
30 and 40min from the start of influx
measurement. Uptake of 3H-vindesine in the
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Figure 4 Response profiles for survival of (a) PGl9 (murine), (b) B8 and (c) BlO (human) melanoma cells at
a constant (10-7 M) concentration ofetretinate and grown in molar concentrations ofvindesine.
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Figure 5 Response profiles for survival of (a) PGl9 (murine), (b) B8 and (c) BlO (human) melanoma cells at
a constant (10 1- M) concentration ofvindesine and grown in molar concentrations of etretinate.
absence of etretinate by the two human melanoma
cell lines was identical, but the murine melanoma
exhibited saturation of uptake at only 72.1% of this
amount (Table II). Unlabelled etretinate had a
minimal stimulatory influence on uptake of 3H-
vindesine by the B8 human melanoma, but did
elevate the saturable uptake by over 20% for the
PGl9 (murine) and BlO (human) melanomas (Table
II).
3H-etretinate Entry of tritium labelled etretinate
by the three cell lines gave virtually identical
profiles which are shown in Figure 7. The uptake of
etretinate reached a plateau by 20 min from the
start of influx measurements for all the cell lines.
The amounts taken by the cell lines are listed in
Table III. The addition of vindesine (10-6 M) did
not influence the uptake of etretinate by the cells at
equilibrium although uptake over the initial period
was greater. In contrast, the PG19 murine
melanoma took up on average 13.9% more 3H-
etretinate than either of the human melanomas
(Table III). In the presence of unlabelled vindesine
3H-etretinate uptake was not altered in any cell line
and PG19 3H-etretinate uptake was maintained at
14.4% greater than for either human cell line
(Table III).
Discussion
The most obvious difference between the two
agents studied was the lack of cytotoxic effect of
etretinate (Figure 2) particularly with regard to the
two human melanoma cell lines. This is in
agreement with the uptake data which indicates
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Figure 6 Time course of uptake of 3H-vindesine
(10-6 M) by (a) PGl9 (murine), (b) B8 and (c) BO0
(human) melanoma cells. Cells were incubated with a
constant amount of [3H]-labelled drug and the uptake
measured in the absence (control) (A) or presence (A)
of unlabelled etretinate (10-6 M).
Table II Amount of 3H-vindesine taken up by the cells
40min from the start of influx measurements. The effect
of etretinate is also shown as a percentage of the control
3H-vindesine uptake per 5 x 105 cells at equilibrium
Cell line Control 10-6 M
etretinate % ofcontrol
d.p.m. ng d.p.m. ng
B8 12,200 4.68 12,400 4.75 101.5
B10 12,200 4.68 15,400 5.90 126.1
PG19 8,800 3.37 10,600 4.06 120.5
that uptake of 3H-etretinate by the murine
melanoma was greater than for either of the human
melanomas (Table IV).
In contrast to etretinate all the cell lines were
sensitive to vindesine (Figure 1). The Do values for
the PG19 and BlO cell lines (Table I) correlate with
the intracellular concentration of vindesine (Table
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Figure 7 Time course of uptake of 'H-etretinate
(10-6M) by (a) PG19 (murine), (b) B8 and (c) B1O
(human) melanoma cells. Cells were incubated with a
constant amount of [3H]-labelled drug and the uptake
measured in the absence (control) (A) or presence (0)
of unlabelled vindesine (10-6 M).
Table III Amount of 3H-etretinate taken up by the cells
40min from the start of influx measurements. The effect of
vindesine is also shown as a percentage of the control
3H-etretinate uptake per 5 x 105 cells at equilibrium
Cell line Control 10-6 M
vindesine % ofcontrol
d.p.m. ng d.p.m. ng
B8 28,000 24.80 28,400 25.16 101.4
BIO 29,100 25.78 28,400 25.16 97.6
PG19 32,500 28.79 32,500 28.79 100.0
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Table IV Theoretical intracellular concentrations of
vindesine and etretinate in the absence (control) and
presence (+) of either agent
Concentration [ x 10-6 M]
Kndesine Etretinate
Cell line Control+etretinate Control+vindesine
B8 2.40 2.44 12.78 12.96
B10 3.06 3.86 16.88 16.48
PG19 7.46 8.98 63.62 63.62
Cell volumes were determined using a Coulter Counter
(model ZB1) and intracellular drug concentrations
calculated assuming that the agents are totally free within
the cell.
IV). However, the B8 cell line had the greatest
sensitivity and the lowest intracellular concentration
of vindesine indicating an intrinsic sensitivity to this
agent. In the presence of 10-7 M etretinate (which
exhibits some degree of toxicity) the Do values for
vindesine were decreased (Table I) indicating
increased sensitivity, which agrees with the uptake
data (Tables II and IV). In contrast, the ID50
values for vindesine in the presence of 10-' M
etretinate were essentially unaltered (Table I).
In the presence of 10-I M vindesine (Figure 5)
the B8 curve is moved, which indicates that
vindesine does not enhance the cytotoxicity of
etretinate but that vindesine toxicity is
superimposed on that of etretinate. However,
vindesine 10-11 M appears to increase the toxicity
of etretinate when the survival at 10-6 M is
compared for the B8 cells although no similar effect
was noted for the other cell lines (Figures 2 and 5).
Since neither agent stimulated uptake by the B8
cells of the other, this must reflect an intrinsic
sensitivity of this cell line to vindesine which is then
enhanced at a high concentration of retinoid. In the
presence of an equimolar mixture of drugs the Do
values for vindesine were variably altered although
the ID50 values showed decreases of 4X (PG19), 9X
(B8) and 2X for the B1O cells. This would indicate
that essentially there is a small synergistic effect
with an equimolar mixture.
This work is the first to report, at the cellular
and molecular level, on the interactions between
vindesine and an aromatic retinoid, etretinate, as a
possible form of combination chemotherapy for the
treatment of malignant melanoma. The results
indicate that vindesine does not affect the uptake of
etretinate by the cells. However, the converse effect
of etretinate stimulation of vindesine uptake occurs
at least in two of the cell lines studied and this may
account for the enhanced cytotoxicity of vindesine
in combination with etretinate. Since the cells used
in the drug uptake studies were not exposed to
either agent prior to the experiments the rapid,
etretinate enhanced vindesine uptake would suggest
a direct membrane effect as the most likely
explanation. The absence of etretinate stimulation
of vindesine uptake with the B8 cells is interesting
because this cell line exhibited the greatest
sensitivity to vindesine alone (Do value) although
the ID50 value was similar to the other cell lines
indicating a lower toxic concentration threshold for
the B8 cells.
In the presence of an equimolar mixture of
etretinate and vindesine the Do values indicate that
only the B10 cells are more sensitive to vindesine
whereas the ID50 values indicate that the toxicity to
vindesine for all the cell lines is between 2X and 9X
greater. In the presence of a relatively high
concentration of etretinate (10 M) the Do values
for vindesine indicated a 5X to lOX greater
sensitivity than for the equimolar mixture for all
the cell lines and (for the PGl9 and B1O cell lines)
at least a lOX greater sensitivity than for vindesine
alone. Although the B8 cells were unaffected, the
results suggest that etretinate is having a sensitising
effect on the toxicity threshold to vindesine. All the
cell lines had ID50 values, in the presence of
10- M etretinate, that were almost the same as for
vindesine alone. Only in the presence of an
equimolar mixture is there an increase in sensitivity
(ID50) compared to vindesine alone, with the B8
cells being the most responsive. Because retinoids
are reported to inhibit cells in the G1 phase of the
cell cycle (Lotan et al., 1982) and vindesine is
reported to kill cells in S phase (Hill & Whelan,
1980) a low etretinate concentration may
synchronise cells in G1 and then allow them to
progress into S phase where vindesine can exert its
toxic effect. A high etretinate concentration may
actually maintain cells in G1 and so protect them
from vindesine toxicity.
It is unlikely that uptake per se can be used to
explain the observed differences since efflux of
vinca alkaloids is also relevant (Hill et al., 1984).
Rather it is the actual intracellular concentration
combined with the intrinsic sensitivity of the cell
line that determines the toxic response and the
etretinate stimulated uptake of vindesine in the
PG19 and B1O cells could account for the enhanced
toxic effects. Etretinate taken up by the PG19 cells
is present at a 4-5 fold higher concentration than in
the B8 or B1O cells and this may account for the
greater sensitivity of this cell line. In the presence of
10-7 M etretinate there is increased sensitivity to
vindesine (Do). The ID50 value is virtually the same
however, which may indicate some stabilising effectCYTOTOXICITY OF ETRETINATE AND VINDESINE 375
of etretinate at a high concentration. This is
supported by the reduction of all the ID50 values
for the equimolar mixture.
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